Yongqing Feng, MD
Internal Medicine · Rowland Heights, CANPI 1497806988
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AstraZeneca at 59.9% of the total. Reporting peaked in 2022 at $303 and has fallen 60.9% since, to $118 in 2025.
Across 48 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$713
- Merck$86
- GSK$73
- Dexcom, Inc.$60
- Johnson & Johnson$51
- Boehringer Ingelheim$47
- plus $160 from 8 others
What the payments were for
- Food & beverage$1,190100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $713 |
| Merck | 4 | $86 |
| GSK | 3 | $73 |
| Dexcom, Inc. | 2 | $60 |
| Johnson & Johnson | 2 | $51 |
| Boehringer Ingelheim | 2 | $47 |
| Redhill Biopharma Inc. | 2 | $38 |
| Nestle Healthcare Nutrition Inc. | 1 | $28 |
| AbbVie | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Amgen | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $13 |
| Novartis | 1 | $11 |
How this compares
$1,190 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 171 | $145,540 |
| JanuviaSitagliptin Phosphate | 83 | $81,451 |
| JardianceEmpagliflozin | 83 | $77,256 |
| CreonLipase/Protease/Amylase | 56 | $63,378 |
| Xigduo XrDapaglifloz Propaned/Metformin | 74 | $58,063 |
| RestasisCyclosporine | 40 | $40,701 |
| JanumetSitagliptin Phos/Metformin Hcl | 45 | $36,168 |
| XareltoRivaroxaban | 46 | $35,858 |
| Cyclosporine | 71 | $31,289 |
| VascepaIcosapent Ethyl | 55 | $29,955 |
| VemlidyTenofovir Alafenamide | 16 | $25,348 |
| LinzessLinaclotide | 35 | $24,609 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $18,543 |
| Diclofenac Sodium | 17 | $16,560 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $14,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Lokelma | $713 | $173,253214 claims |
| AbbVieCreon, Restasis, Linzess | $21 | $128,688131 claims |
| MerckJanuvia, Janumet | $86 | $117,619128 claims |
| Boehringer IngelheimJardiance, Synjardy | $47 | $87,84998 claims |
| Johnson & JohnsonXarelto | $51 | $35,85846 claims |
| GSKTrelegy Ellipta | $73 | $14,46023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Rowland Heights
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.